Anlon Healthcare

Anlon Healthcare FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Anlon Healthcare (AHCL.NS) as of Nov 16, 2026 is -406.49 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -112.49 % — a change of 261.35% (lower).

FCF Conversion

-406.49 %

YoY

261.35%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Anlon Healthcare is 2026 -406.49 % . FCF Conversion Rate (FCF/EBITDA) of Anlon Healthcare was 2025 -112.49 % . It decreases by 261.35% lower compared to the previous year.

The Anlon Healthcare FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
2,072.79 INR
Jan 1, 2023
-55.36 INR
Jan 1, 2024
-69.98 INR
Jan 1, 2025
-112.49 INR
Jan 1, 2026
-406.49 INR
The Anlon Healthcare FCF Conversion history
YEARFCF ConversionYoY
-406.49 %+261.35%
-112.49 %+60.76%
-69.98 %+26.40%
-55.36 %-102.67%
2,072.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Anlon Healthcare Stock analysis

What does Anlon Healthcare do? Anlon Healthcare Ltd. generates revenue through the production and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), nutraceutical APIs, and ingredients for personal care and veterinary applications. Its product portfolio includes 3-(1-cyanoethyl) benzoic acid (CEBA), ketoprofen ethyl ester (KEE), Dex-Ketoprofen, Loxoprofen Acid, Ketoprofen, Silodosin, Omeprazole, L-Arginine, Piroctone olamine, Ticagrelor, and other specialized compounds. The company targets pharmaceutical manufacturers, nutraceutical producers, and personal care and veterinary product developers as its primary customers, serving the broader healthcare and wellness industry segments. The business model focuses on supplying high-quality chemical compounds used in the formulation of medicines and health-related products. Anlon Healthcare Ltd. leverages its expertise in chemical synthesis to deliver tailored solutions for clients in the pharmaceutical sector, ensuring compliance with industry standards. Its product range supports diverse applications, from human medicine to veterinary care and personal care products, enabling it to serve multiple market segments with a single production infrastructure. Revenue streams are derived from direct sales of its chemical products to manufacturers across pharmaceutical, nutraceutical, personal care, and veterinary industries. The company's offerings are designed to meet the specific needs of these sectors, with products like Omeprazole for gastrointestinal treatments and Ticagrelor for cardiovascular care. By providing essential raw materials, Anlon Healthcare Ltd. positions itself as a critical supplier within the healthcare supply chain. Anlon Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Anlon Healthcare stock

FCF Conversion Rate (FCF/EBITDA) of Anlon Healthcare is -406.49 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Anlon Healthcare changed from -112.49 % to -406.49 %, representing a 261.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Anlon Healthcare since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Anlon Healthcare with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Anlon Healthcare

All Key Metrics — Anlon Healthcare